2.1. Study Design and Setting
allergy, liver dysfunction, thyroid disease
CARDIOPULMONARY DISEASE, THYROID DISEASE, BLOOD COAGULATION DISORDER, ALLERGY, CRANIAL NERVE DISEASE
This prospective controlled study was reviewed and approved by the Institutional Review Board. Informed written consent was obtained from all patients, and the trial was registered at Patients with a history of thyroid disease, cardiopulmonary disease, blood coagulation disorder, liver dysfunction, cranial nerve disease, alcohol or drug abuse, a known allergy to the study drug, and those who had a core BT >38 °C or <36.5 °C, a BMI >30 kg/mRandomization, with two block sizes, was stratified using 1:1 allocation (using computerized random numbers). All patients were randomly allocated to either the sevoflurane group (group S) or the remimazolam group (group R). The attending anesthesiologists who checked the outcomes in the PACU were blinded to the study protocol.